CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Phase 2b Clinical Trial

esperion

Esperion Starts Next Phase Of Cholesterol Drug Trial

The Plymouth pharma startup Esperion Therapeutics Inc. (Nasdaq: ESPR), Wednesday announced the first patient in a Phase 2b clinical study had received the first dose of ETC-1002, its lead anti-cholesterol drug.

WWJ Newsradio 950–10/30/2013